19 Jun 2013
Two phase III trials of 84 blind patients from 34 medical centers in the United States and Germany, presented to ENDO 2013, assesses the effects of a melatonin receptor agonist to entrain circadian rhythms and improve sleep quality in non-24 hour sleep-wake disorder.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024